Viridian Therapeutics (VRDN) Revenue & Revenue Breakdown
Viridian Therapeutics Revenue Highlights
00
Main Segment (Y)
Collaboration Revenue
Viridian Therapeutics Revenue by Period
Viridian Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $314.00K | -82.28% |
| 2022-12-31 | $1.77M | -40.20% |
| 2021-12-31 | $2.96M | 182.19% |
| 2020-12-31 | $1.05M | -76.46% |
| 2019-12-31 | $4.46M | -46.80% |
| 2018-12-31 | $8.39M | 109.49% |
| 2017-12-31 | $4.00M | 19.96% |
| 2016-12-31 | $3.34M | 31.48% |
| 2015-12-31 | $2.54M | -41.25% |
| 2014-12-31 | $4.32M | 0.08% |
| 2013-12-31 | $4.32M | -2.03% |
| 2012-12-31 | $4.41M | - |
Viridian Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Viridian Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | -100.00% |
| 2025-03-31 | $72.00K | - |
| 2024-12-31 | $72.00K | -16.28% |
| 2024-09-30 | $86.00K | 19.44% |
| 2024-06-30 | $72.00K | - |
| 2024-03-31 | $72.00K | - |
| 2023-12-31 | $72.00K | - |
| 2023-09-30 | $72.00K | - |
| 2023-06-30 | $72.00K | -26.53% |
| 2023-03-31 | $98.00K | -6.67% |
| 2022-12-31 | $105.00K | -91.21% |
| 2022-09-30 | $1.20M | 366.80% |
| 2022-06-30 | $256.00K | 18.52% |
| 2022-03-31 | $216.00K | 0.93% |
| 2021-12-31 | $214.00K | 2.88% |
| 2021-09-30 | $208.00K | -80.92% |
| 2021-06-30 | $1.09M | -24.88% |
| 2021-03-31 | $1.45M | 2587.04% |
| 2020-12-31 | $54.00K | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $168.00K | -79.71% |
| 2020-03-31 | $828.00K | -5.91% |
| 2019-12-31 | $880.00K | 26.62% |
| 2019-09-30 | $695.00K | -72.35% |
| 2019-06-30 | $2.51M | 575.81% |
| 2019-03-31 | $372.00K | -21.85% |
| 2018-12-31 | $476.00K | -49.58% |
| 2018-09-30 | $944.00K | -56.74% |
| 2018-06-30 | $2.18M | -54.39% |
| 2018-03-31 | $4.78M | 301.34% |
| 2017-12-31 | $1.19M | -26.92% |
| 2017-09-30 | $1.63M | 127.16% |
| 2017-06-30 | $718.00K | 55.41% |
| 2017-03-31 | $462.00K | -38.89% |
| 2016-12-31 | $756.00K | -14.96% |
| 2016-09-30 | $889.00K | 1.72% |
| 2016-06-30 | $874.00K | 6.85% |
| 2016-03-31 | $818.00K | 24.13% |
| 2015-12-31 | $659.00K | 31.54% |
| 2015-09-30 | $501.00K | -31.74% |
| 2015-06-30 | $734.00K | 13.80% |
| 2015-03-31 | $645.00K | -1.45% |
| 2014-12-31 | $654.52K | -49.69% |
| 2014-09-30 | $1.30M | 2.15% |
| 2014-06-30 | $1.27M | 16.74% |
| 2014-03-31 | $1.09M | 0.03% |
| 2013-12-31 | $1.09M | 10.88% |
| 2013-09-30 | $983.59K | -10.82% |
| 2013-06-30 | $1.10M | -3.20% |
| 2013-03-31 | $1.14M | - |
Viridian Therapeutics generated - in revenue during Q2 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Viridian Therapeutics Revenue Breakdown
Viridian Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Collaboration Revenue | $300.00K | $300.00K | $1.80M | $2.96M | $735.00K |
| Grant | - | - | - | - | $315.00K |
Latest
Viridian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | - | $100.00K | $100.00K | $100.00K | $100.00K | $1.20M | $300.00K | $200.00K | $208.00K | - | - | $54.00K | - | $837.00K | - |
| Grant | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $168.00K | $43.00K | - |
| Collaboration Revenue, Related Party | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.09M | $1.45M | - | - | - | - |
| Reimbursement Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $700.00K | $837.00K |
Latest
Viridian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Collaboration Revenue (100.00%).
Viridian Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RCUS | Arcus Biosciences | $258.00M | $28.00M |
| OCUL | Ocular Therapeutix | $63.46M | $13.39M |
| ABCL | AbCellera Biologics | $28.83M | $4.24M |
| JANX | Janux Therapeutics | $10.59M | - |
| CLDX | Celldex Therapeutics | $7.02M | $695.00K |
| GPCR | Structure Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| VRDN | Viridian Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| VERA | Vera Therapeutics | - | - |
| BHVN | Biohaven | - | - |